Regarding ASA treatment after diagnosis of CRC, survival benefit was only observed in patients with mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene). This evidence concerns the gene PIK3CA and colorectal carcinoma.